ChemoCentryx Inc (NASDAQ:CCXI) was the recipient of unusually large options trading on Tuesday. Investors purchased 1,122 call options on the stock. This is an increase of 1,802% compared to the typical volume of 59 call options.

In related news, CFO Susan M. Kanaya sold 37,893 shares of the stock in a transaction dated Tuesday, January 22nd. The stock was sold at an average price of $12.08, for a total value of $457,747.44. Following the completion of the sale, the chief financial officer now directly owns 110,746 shares of the company’s stock, valued at approximately $1,337,811.68. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas J. Schall sold 5,755 shares of the stock in a transaction dated Friday, March 29th. The stock was sold at an average price of $14.00, for a total value of $80,570.00. Following the completion of the sale, the chief executive officer now directly owns 2,234,610 shares of the company’s stock, valued at $31,284,540. The disclosure for this sale can be found here. Over the last three months, insiders sold 238,648 shares of company stock valued at $3,190,267. Company insiders own 14.50% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. Strs Ohio raised its stake in shares of ChemoCentryx by 6.5% in the 4th quarter. Strs Ohio now owns 55,800 shares of the biopharmaceutical company’s stock valued at $608,000 after acquiring an additional 3,400 shares in the last quarter. MetLife Investment Advisors LLC raised its stake in shares of ChemoCentryx by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 19,233 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 6,841 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in ChemoCentryx by 369.8% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,804 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 6,930 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in ChemoCentryx by 6.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 126,848 shares of the biopharmaceutical company’s stock valued at $1,604,000 after buying an additional 8,070 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in ChemoCentryx by 44.9% in the 4th quarter. Rhumbline Advisers now owns 30,596 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 9,479 shares during the last quarter. 54.11% of the stock is currently owned by institutional investors and hedge funds.

CCXI opened at $13.64 on Wednesday. ChemoCentryx has a fifty-two week low of $9.07 and a fifty-two week high of $14.98. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.82 and a quick ratio of 2.82. The stock has a market cap of $714.49 million, a PE ratio of -17.95 and a beta of 1.31.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.06. ChemoCentryx had a negative return on equity of 167.57% and a negative net margin of 88.55%. The business had revenue of $9.33 million for the quarter, compared to the consensus estimate of $9.54 million. On average, research analysts forecast that ChemoCentryx will post -1.17 EPS for the current fiscal year.

Several equities research analysts recently issued reports on the company. Zacks Investment Research downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Tuesday, February 26th. ValuEngine raised ChemoCentryx from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company’s stock. ChemoCentryx presently has a consensus rating of “Buy” and a consensus target price of $18.14.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/chemocentryx-target-of-unusually-high-options-trading-ccxi/2952703.html.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.

Read More: How does new data get added to a blockchain?

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.